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Abstract: Neurofibromatosis type I, a genetic disorder due to mutations in theNF1 gene, is characterized
by a high mutation rate (about 50% of the cases are de novo) but, with the exception of whole
gene deletions associated with a more severe phenotype, no specific hotspots and few solid
genotype/phenotype correlations. After retrospectively re-evaluating all NF1 gene variants found in
the diagnostic activity, we studied 108 patients affected by neurofibromatosis type I who harbored
mutations that had not been previously reported in the international databases, with the aim of
analyzing their type and distribution along the gene and of correlating them with the phenotypic
features of the affected patients. Out of the 108 previously unreported variants, 14 were inherited by
one of the affected parents and 94 were de novo. Twenty-nine (26.9%) mutations were of uncertain
significance, whereas 79 (73.2%) were predicted as pathogenic or probably pathogenic. No differential
distribution in the exons or in the protein domains was observed and no statistically significant
genotype/phenotype correlation was found, confirming previous evidences.
Keywords: neurofibromatosis type I; NF1 gene; genotype/phenotype correlation
1. Introduction
The rapid evolution of the high-throughput sequencing technologies presents significant
challenges in the acquisition, analysis and interpretation of large data sets. In particular, the detection
of several novel alleles in multiple-gene panels or clinical exomes brings about difficulties in the
understanding of the significance of the variants found and finally in the interpretation and clinical use
of the genetic result in settings like pre-symptomatic or prenatal diagnosis [1,2]. Disease-specific
databases, knowledge of the allele frequencies and the type of nucleotide change help to sort
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single variants into benign or pathogenic, but some of them remain uncertain about their clinical
significance [3], especially when they are found in genes causing very rare diseases or those with a
reduced penetrance or with a high mutation rate [4]. The approach to the interpretation of single
variants used for genes such as NF1 or BRCA1 [1,5], based on a distribution into classes of growing
evidence of pathogenicity (five, at present), has then been translated to the interpretation of the results
of clinical exomes or large gene-panels.
In addition to providing a strategy for the clinical use of new gene variants, NF1 (MIM*613113) is a
model gene for the high rate of new alleles (about 50% of the total burden of mutations [6]) and for their
fully penetrant mendelian behavior, which makes them detectable in specific phenotypes belonging to
neurofibromatosis type I (NF1) (MIM#162200) (various combinations of multiple café-au-lait spots,
axillary and inguinal freckling, multiple neurofibromas, and iris Lisch nodules) [7]. Understanding
the features of the NF1 novel variants can shed light on the patterns of genome variability, natural
selection, and evolution.
Moreover, the clinical phenotypic expression characterized by marked intra- and inter-familial
variability with multisystemic complications including neurological, cardiovascular, gastrointestinal,
endocrine, neoplastic, and orthopedic features [8] has long puzzled physicians and researchers in the
attempt to predict which genotypes would harbor the highest risk of complications. Very few, however,
are the established genotype–phenotype correlations, whose best example is represented by the NF1
extended deletions, which have been linked to a more severe phenotype than point mutations [9–11].
Finally, no evidence exists demonstrating that mutations cluster in specific gene regions or protein
domains of which the NF1 protein, neurofibromin, is composed, including a cysteine–serine-rich
domain (CSRD), a tubulin-binding domain (TBD), a central GTPase-activating protein-related (GRD),
a SEC14 domain, a syndecan binding 1 (SH1) domain, a pleckstrin homology (PH) domain, a syndecan
binding 2 (SH2) domain, and a carboxy-terminal domain (CTD) [12].
In the present study, we retrospectively re-evaluated all NF1 gene variants found in 17 years of
diagnostic activity and selected all the mutations not reported in the international databases or in the
medical literature. Those latter were stratified according to the five pathogenetic classes, analyzed for
their type and their distribution in the exons of the NF1 gene and in the domains of the relative protein.
Finally, after dividing the phenotypic features of the disease into cardinal signs and complications, a
genotype/phenotype correlation was attempted according to the type and site of the variant found.
2. Results
Out of the 502 patients with a clinical diagnosis of neurofibromatosis type I, 108 harbored
mutations that had never been previously reported in the international disease databases (Table S1).
Among those, 45 were single-base substitutions (26 missense, 10 truncating, 6 splice-site, and 3
synonymous), 44 small deletions, (41 truncating, 2 in-frame, and 1 splice-site), 12 duplications (all
producing truncating protein), 5 indels (4 truncating and 1 in-frame), 1 insertion (truncating), and 1
large deletion spanning Exons 2–19 (Table 1).
Table 1. Classification of the previously undescribed NF1 mutations.
Type of Mutation, n Missense (%) Truncating (%) Splice (%) Silent (%) In-Frame (%)
Single Nucleotide Variants, 45 26 (57.8) 10 (22.2) 6 (13.3) 3 (6.7) 0 (0)
Small Deletions, 44 0 (0) 41 (93.2) 1 (2.3) 0 (0) 2 (4.5)
Small Duplications, 12 0 (0) 12 (100) 0 (0) 0 (0) 0 (0)
Indels, 5 0 (0) 4 (80) 0 (0) 0 (0) 1 (20)
Insertions, 1 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
Large Deletions, 1 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
Total, 108 26 (24) 69 (63.9) 7 (6.5) 3 (2.8) 3 (2.8)
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Truncating variants are the most frequently encountered alterations in our population (69/108;
63.9%), followed by missense (26/108; 24%), splice-site (7/108; 6.5%), synonymous (3/108; 2.8%), and
in-frame variants (3/108; 2.8%) (Table 1). Out of the 108 previously undescribed NF1 alleles, 14 were
familial (inherited by one of the two parents presenting signs and symptoms of NF1) and 94 de novo.
Twenty-nine (26.9%) variants were of unknown significance (25 missense, 3 synonymous, and 1
in-frame), 16 (14.8%) were likely pathogenic (7 splice-site, 8 truncating, and 1 missense) and 63 (58.3%)
variants were pathogenic (61 truncating and 2 in-frame) (Table 2).
Table 2. Classification of the NF1 mutations according with pathogenicity score.
Mutation Type, n (%)
Pathogenity Score, n (%)
1 2 3 4 5
Missense, 26 (24) 0 (0) 0 (0) 25 (96.1) 1 (3.9) 0 (0)
Truncating, 69 (63.9) 0 (0) 0 (0) 0 (0) 8 (11.6) 61 (88.4)
Splicing, 7 (6.5) 0 (0) 0 (0) 0 (0) 7 (100) 0 (0)
Silent, 3 (2.8) 0 (0) 0 (0) 3 (100) 0 (0) 0 (0)
In-frame, 3 (2.8) 0 (0) 0 (0) 1 (33.3) 0 (0) 2 (66.7)
Total, 108 0 (0) 0 (0) 29 (26.9) 16 (14.8) 63 (58.3)
The distribution of the previously unreported variants in the NF1 gene showed that no mutational
hotspots exist in the gene and that the most frequently hit exons (including the flanking introns, +/−2 bp)
were Exons 13, 27, 37 (7 mutations), 8, 32, 42 (6 mutations), and 32 (5 mutations) (Figure 1a).
Five out the 108 mutations (4.6%) were located within CpG dinucleotides. When the functional
domains of the protein neurofibromin 1 were considered, 13 (12%) mutations were identified in
the CSRD domain, 3 (2.8%) in TBD, 11 mutations (10.2%) in GRD, 10 (9.3%) in GRD/S1, 4 (3.7%) in
SEC14-SEC14P, 1 (0.9%) in SEC14/PH, 2 (1.8%) in PH, 11 (10.2%) in CTD, and 1 (0.9) in CTD/S2.
Furthermore, 52 (48.2%) mutations were localized outside the neurofibromin domains (Figure 1b).
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Figure 1. (a) Distribution of the NF1 variants by exons. (b) Distribution of the variants in neurofibromin
domains. CSRD: cysteine–serine-rich domain; TBD: tubulin-binding domain; GRD: GTPase-activating
protein-related domain; S1: syndecan binding domain 1; PH: pleckstrin homology domain;
CTD: carboxy-terminal domain; S2: syndecan binding domain 2; SEC14/ SEC14p: Sec14-like lipid
binding module.
Twenty-nine variants (26.9% of the total) were classified as variants of unknown significance
(VUS, Score 3), 16 (14.8%) as likely pathogenetic (Score 4) and 63 (58.3%) as pathogenetic (Score 5).
De novo variants were assigned to Classes 4 and 5 in 73.4% (69 out of 94) of cases, whereas the familial
ones were attributed to Class 4 or Class 5 in 71.4% (10 out of 14) of cases, χ-square = 0.004, p = 1)
(Table 2 and Table S2).
As far as the phenotypic features were concerned (details of each patient are reported in
Table S2), a higher proportion of specific NF1 features was found in patients with truncating
mutations, compared to patients with non-truncating ones (the 7 splice-site variants were excluded
from this analysis due the lack of functional data about their effect on the protein), but none of the
differences found reached statistical significance (cafe-au-lait patches (CALs): 97.8% vs. 92.9% for
truncating mutations vs. non-truncating mutations, respectively, p = 1; axillary or groin freckling
(AIF): 71.1% vs. 50%, p = 0.49; Lisch nodules (LN): 26.2% vs. 21.4%, p = 0.78; cutaneous/subcutaneous
neurofibromas (CN/SN): 55.6% vs. 42.9%, p = 0.63; plexiform neurofibromas (PN): 13.3% vs. 7.1%,
p = 0.57; optic pathway glioma (OPG): 11.1% vs. 7.1%, p = 0.69; neoplasms: 0% vs. 0%, p = 1; sphenoid
wing dysplasia (SD): 7.3% vs. 0%, p = 0.19; cognitive deficit (CD): 11.4% vs. 21.4%, p = 0.42; scoliosis
(S): 26.7% vs. 14.3%, p = 0.44, hypertension (H): 11.1% vs. 7.1%, p = 0.70) (Figure 2a). After the
phenotypic features were grouped into cardinal signs (CALs, AIF, and LN) and complications (all the
other signs), no significant differences were found between patients with truncating mutations vs.
those with non-truncating mutations (17.2% vs. 12.5%, p = 0.31) (Figure 2b). The average paternal age
in de novo mutations (36 years and 4 months) was higher than that in familial mutations (35 years),
but, again, no statistically significant differences were found.
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Figure 2. (a) Clinical features and (b) aggregation of cardinal signs and complications in patients
with truncating and non-truncating mutations. CALs: café-au-lait patches; AIF: axillary or groin
freckling; LN: Lisch nodules; CN/SN: cutaneous/subcutaneous; PN: plexiform neurofibromas; OPG:
optic pathway glioma; SD: sphenoid wing dysplasia; CD: cognitive deficit; S: scoliosis; H: hypertension.
3. Discussion
Neurofibromatosis type I is a model genetic disorder due to the high mutation rate of its
causative gene, NF1 [6]. However, despite the long-standing knowledge of the disease, studies of the
genotype/phenotype correlation have failed to find clear associations with specific gene variations [13,14],
probably due to the tumor suppressor mechanism of the NF1 gene, which acts in a recessive manner
and requires a second random somatic, occult mutational event for its expression [15,16]. For these
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reasons, the majority of studies have yielded negative results [13,14,17], and very few have reported
mutation-specific correlations: a 3 bp in-frame deletion, c.2970_2972delAAT, has been related to the
absence of cutaneous neurofibromas [18,19], and missense mutations affecting codon 1809 (Arg1809Cys)
have been associated with Noonan-like dysmorphisms and the absence of neurofibromas [20,21].
More general observations have indicated a poorer cognitive prognosis and a higher risk of tumors,
neurofibromas, and MPNSTs for the whole NF1 gene deletions [9–11]; other reports have hypothesized
an association of splice-site mutations with an increased tendency to develop neoplasms [22],
of truncating mutations with the presence of Lisch nodules and CALs [23,24] and of non-truncating
mutations with pulmonary stenosis [25]. The results of our study show that, starting from a population
of affected patients, there are no hotspots for mutations in the NF1 gene, nor is there any preferential
involvement of specific protein domains. We did not observe any significant correlation between
the type of mutation and the phenotypic features, both taken individually (Figure 2a) and grouped
together (Figure 2b). Moreover, no malignancies were registered (Figure 2a), possibly due to the young
age of the population tested (median age 25 years and 5 months). In conclusion, our data confirm the
majority of the previous studies about the weak predictive potential in clinical terms of the mutation
found, which cannot be applied in individual cases, especially in predictive counselling settings like
the prenatal diagnosis or when formulating the disease prognosis of an affected child.
Another focus of our study was to highlight potential factors involved in the high mutation rate in
the NF1 gene, for which two main risk factors have been advocated: the paternal age of the affected [26]
and the genomic context [27], which are the common determinants of the genetic variability at the
nucleotide level [28]. Considering our population, the paternal age at birth was slightly higher in
de novo mutations (mean age 36 years and 4 months) than in familial ones (mean 35 age), although
no statistically significant association was found, also probably due to a type 2 statistical error for the
limited number of observations in the familial group (14 cases). The context, i.e., the identity of the
nucleotides surrounding the mutation, had clearly no impact on the mutational load, since only 5 of 108
fell into the CpG dinucleotides, the most mutable sequences in humans [27]. Regardless of the cause,
the high variability of the gene is evident when querying the ClinVar database [3] for all known NF1
exonic variants (including splice-site +/− 2 bp): the reported mutations occur, on average, in one out
of every eight nucleotides—mostly missense (74%), followed by truncating (20%), and splice-site (6%).
They present an inverted ratio compared to our NF1 cohort, in which the most common mutation group
is represented by the truncating (63.9%) variations, followed by missense (24%) and splice-site (6.5%)
variations. This difference is reflected in the clinical significance of the variant found (for truncating
mutations, it is easier to foresee a causal role for the disease), which in the ClinVar database was in 44%
of the cases considered as VUS, a ratio that in our cohort was 26.9% (29/108), a lower but still relevant
percentage of tests with inconclusive results about pathogenesis.
In conclusion, the present genotype/phenotype correlation study based on 108 previously
undescribed NF1 variants failed to show any gene hotspot for mutation and any significant association
of the clinical presentation of the disease with the type of gene mutation found. In at least one fourth
of the cases, the clinical significance of the variant found at the genetic testing remains uncertain,
with important reflections on the genetic counseling of the patients and their families.
4. Materials and Methods
4.1. Patients
The analysis is based on the records of Parma University Hospital’s Unit of Medical Genetics,
covering the years 2000 to 2017. The laboratory functions as a hub for the entire Emilia Romagna
Region (4.5 million inhabitants) and attracts patients from other Italian regions as well. Genetic
testing was performed on patients having a clinical suspicion of neurofibromatosis type I based
on the presence of at least two of the clinical manifestations proposed by the National Institute of
Health Consensus Development Conference, i.e., the presence of six or more CALs >15 mm in adults
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and >5 mm in children, two or more CN/SN or PN, AIF, LN, OPG, MPNST, PCC, CD, and distinctive
osseous lesions such as SD or S [29]. Each sample given to our laboratory was accompanied by a
clinical chart in which a clinical description of the patient was reported. Patient’s clinical records,
genealogical trees, and genetic test results were all collected and archived in a specifically dedicated
Excel file. In the 2000–2017 period, 502 subjects with a clinical suspicion of neurofibromatosis type I
were subjected to genetic testing as part of the diagnostic process.
4.2. NF1 Genetic Test
From April 2000 to June 2016 (397 out of the total 502 patients, 79.1%), genetic analyses on genomic
DNA were conducted using denaturing high pressure liquid chromatography (DHPLC), which exploits
the differential retention of homoduplex and heteroduplex DNA under conditions of partial thermal
denaturation (reported detection rate for NF1 mutations: 72% [30]). Primer pairs were designed
according to the published reference genomic NF1 sequence (GenBank accession number NG_009018.1).
To characterize the samples with a profile different from a wild-type control, direct sequencing of the
fragments was performed using M13 Universal primers and a GenomeLab DTCS Quick Start kit for
Dye Cycle Sequencing on a CEQ 2000XL Sequence Analyzer (Beckman Coulter, CA, USA). Starting
from June 2016 (105 out of the total 502 patients, 20.9%), the genetic analyses were performed via
next-generation sequencing using the Illumina MiSeq (TruSeq Custom Amplicon v.1.5, San Diego,
CA, USA) platform (reported detection rate for NF1 mutations: 88% [15]). For the description and
nomenclature of sequence variations at the DNA and protein level, the Mutalyzer software version
2.0.22 [31] was used with the NM_000267.3 reference sequence. Multiplex ligation-dependent probe
amplification (MLPA, MRC Holland Amsterdam, The Netherlands) as been used for the detection of
deletions or duplications spanning one or more exons in those cases negative at the sequencing analysis.
For predicting the pathogenicity of the missense mutations, the REVEL (Rare Exome Variant Ensemble
Learner) tool was used, an Ensemble method based on the 13 most commonly used prediction
software [32].
4.3. The Database
After the consultation of the dedicated international databases (Clinvar [3]; The Human Gene
Mutation Database, HGMD [33]; Leiden Open Variation Database 3.0, LOVD [34]), the previously
undescribed NF1 variants together with the genetic information were grouped and prepared in an
Excel file. In particular, records have included, for each variant, the type, effect, aminoacid change,
exon involved, protein domain, segregation (de novo/familial), and population frequency according
to Ensembl [35] and ExAC [36]. All the information has been submitted to the ClinVar [3] gene
variant database (Accession number: SUB2798650). Moreover, the main clinical features of the patients
with previously undetected mutations were recorded according to the Human Phenotype Ontology
(HPO) [37] (Table 3). Finally, the classical 5-tiered system, which classifies the variants on the basis of
standard criteria [1] as 1 (benign), 2 (likely benign), 3 (uncertain significance), 4 (likely pathogenic),
and 5 (pathogenic) was adopted.
The statistical analysis was performed using the SPSS software (version 10.0, SPSS Corp, Chicago,
IL, USA), converting descriptive variables to numerical values and using the chi-square test to evaluate
differences in mutation distribution among exons and protein domains of neurofibromin and for
genotype–phenotype comparisons between groups. Statistical results were corrected for multiple
testing using Holm’s test [38].
The local Institutional Review Board approval was requested and obtained for this study (Prot.
N. 0051/2017).
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Table 3. Clinical features of patients with novel NF1 mutation.
Clinical Features (HPO Code) Number of Patientswith Known Status
Number of Patients
with Positive Status (%)
Café-au-lait spots (0000957) 59 57/59 (96.6)
Axillary or inguinal freckles (0000997, 0030052) 59 39/59 (66.1)
Lisch nodules (0009737) 56 14/56 (25)
Cutaneous, subcutaneous neurofibromas (0100698, 0100698) 59 31/59 (52.5)
Plexiform neurofibromas (0009732) 59 7/59 (11.9)
Optic pathway glioma (0009734) 59 6/59 (10.2)
Neoplasms (0002664) 59 0/59 (0)
Sphenoid-shank dysplasia (0000924) 55 3/55 (5.4)
Cognitive defects (0100543) 58 8/58 (13.8)
Scoliosis (0002650) 59 14/59 (23.7)
Hypertension (0000822) 59 6/59 (10.2)
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/10/2071/s1.
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